Jay Koyner, MD
Nephrology · Chicago, ILNPI 1275656340
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $96,921 of the $112,913 with a category attached, or 85.8%. 9 manufacturers reported payments, led by Baxter Healthcare at 45.3% of the total. 2025 is the largest year on record at $34,721, 2.3 times the $14,941 reported in 2019. Among nephrology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 84 payments — averaging $1344.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$51K
- AstraZeneca$22K
- Vantive US Healthcare LLC$14K
- Biomerieux Inc$13K
- Mallinckrodt Hospital Products Inc.$6K
- Fresenius USA Marketing, Inc.$4K
- plus $2K from 3 others
Across 30 payments — averaging $4270.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astute Medical, Inc.$47K
- Biomerieux Inc$41K
- Fresenius USA Marketing, Inc.$40K
What the payments were for
- Consulting fees$96,92186%
- Speaking & faculty fees$1,7502%
- Travel & lodging$3,3473%
- Food & beverage$2,2112%
- Education$8,6858%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 26 | $51,141 |
| AstraZeneca | 32 | $22,268 |
| Vantive US Healthcare LLC | 12 | $14,064 |
| Biomerieux Inc | 3 | $13,200 |
| Mallinckrodt Hospital Products Inc. | 2 | $6,225 |
| Fresenius USA Marketing, Inc. | 4 | $3,964 |
| Nxstage Medical, Inc. | 2 | $1,775 |
| Exthera Medical Corporation | 2 | $145 |
| Novartis | 1 | $131 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Renal - Acute$54,424
- ULTOMIRIS$18,807
- NEPHROCHECK$9,000
- NXSTAGE SYSTEM ONE$5,705
- Renal - PrisMax System$4,590
- Renal - Non Product Related$3,740
- Renal - PD$1,400
- Non-Franchise (NOF) - NonProduct$458
How this compares
$112,913 in reported general payments places this provider in the 95th percentile of 524 nephrology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 30 | $32,596 |
| JardianceEmpagliflozin | 17 | $22,117 |
| Calcitriol | 54 | $497 |
| Potassium Chloride | 13 | $391 |
| Lisinopril | 26 | $378 |
| Chlorthalidone | 20 | $318 |
| Losartan Potassium | 36 | $297 |
| Amlodipine Besylate | 23 | $181 |
| Atorvastatin Calcium | 13 | $166 |
| Furosemide | 29 | $130 |
| Prednisone | 18 | $86 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 17 | $38 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $22,268 | $32,59630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 524 nephrology providers in Illinois.
Other nephrology in Chicago
- Myles WolfChicago$2.1M
- Susan QuagginChicago$262K
- Nicole StankusChicago$235K
- Marco BonillaChicago$148K
- Lorenzo GallonChicago$120K
- Vikram AggarwalChicago$117K
- Jose ArrudaChicago$107K
- John FriedewaldChicago$93K
- Casey GashtiChicago$74K
- Amr YafiChicago$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.